SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Clinical trials for SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lupus skin flares: experimental drug shows promise
Disease control Recruiting nowThis study tests an experimental drug called litifilimab for people with active lupus skin disease (subacute or chronic cutaneous lupus) who didn't get better with standard antimalarial therapy. About 450 participants will receive either the drug or a placebo for 24 weeks, then a…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE2, PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 17, 2026 05:06 UTC
-
New hope for lupus skin sufferers: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an investigational drug called IMVT-1402 in people with active lupus skin disease (subacute or chronic cutaneous lupus). About 56 adults will receive either the drug or a placebo for 12 weeks, then all will get the drug for 14 more weeks, followed by a longer ext…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated May 06, 2026 16:13 UTC